196 related articles for article (PubMed ID: 37099070)
1. Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.
Michuda J; Breschi A; Kapilivsky J; Manghnani K; McCarter C; Hockenberry AJ; Mineo B; Igartua C; Dudley JT; Stumpe MC; Beaubier N; Shirazi M; Jones R; Morency E; Blackwell K; Guinney J; Beauchamp KA; Taxter T
Mol Diagn Ther; 2023 Jul; 27(4):499-511. PubMed ID: 37099070
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Gene Expression Profiling in Gastrointestinal Neuroendocrine Tumors of Unknown Primary Origin.
Saller JJ; Haider M; Al-Diffalha S; Coppola D
Anticancer Res; 2022 Mar; 42(3):1381-1396. PubMed ID: 35220231
[TBL] [Abstract][Full Text] [Related]
3. CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence.
Zhao Y; Pan Z; Namburi S; Pattison A; Posner A; Balachander S; Paisie CA; Reddi HV; Rueter J; Gill AJ; Fox S; Raghav KPS; Flynn WF; Tothill RW; Li S; Karuturi RKM; George J
EBioMedicine; 2020 Nov; 61():103030. PubMed ID: 33039710
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
[TBL] [Abstract][Full Text] [Related]
5. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
[TBL] [Abstract][Full Text] [Related]
6. Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with
Gröschel S; Bommer M; Hutter B; Budczies J; Bonekamp D; Heining C; Horak P; Fröhlich M; Uhrig S; Hübschmann D; Geörg C; Richter D; Pfarr N; Pfütze K; Wolf S; Schirmacher P; Jäger D; von Kalle C; Brors B; Glimm H; Weichert W; Stenzinger A; Fröhling S
Cold Spring Harb Mol Case Stud; 2016 Nov; 2(6):a001180. PubMed ID: 27900363
[TBL] [Abstract][Full Text] [Related]
7. An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin.
Tothill RW; Kowalczyk A; Rischin D; Bousioutas A; Haviv I; van Laar RK; Waring PM; Zalcberg J; Ward R; Biankin AV; Sutherland RL; Henshall SM; Fong K; Pollack JR; Bowtell DD; Holloway AJ
Cancer Res; 2005 May; 65(10):4031-40. PubMed ID: 15899792
[TBL] [Abstract][Full Text] [Related]
8. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
[TBL] [Abstract][Full Text] [Related]
10. Overview of various techniques/platforms with critical evaluation of each.
Agwa E; Ma PC
Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
[TBL] [Abstract][Full Text] [Related]
11. An integrated tool for determining the primary origin site of metastatic tumours.
Santos MTD; Souza BF; Cárcano FM; Vidal RO; Scapulatempo-Neto C; Viana CR; Carvalho AL
J Clin Pathol; 2018 Jul; 71(7):584-593. PubMed ID: 29248889
[TBL] [Abstract][Full Text] [Related]
12. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
Hainsworth JD; Greco FA
Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
[TBL] [Abstract][Full Text] [Related]
13. Identification of Tissue of Origin and Guided Therapeutic Applications in Cancers of Unknown Primary Using Deep Learning and RNA Sequencing (TransCUPtomics).
Vibert J; Pierron G; Benoist C; Gruel N; Guillemot D; Vincent-Salomon A; Le Tourneau C; Livartowski A; Mariani O; Baulande S; Bidard FC; Delattre O; Waterfall JJ; Watson S
J Mol Diagn; 2021 Oct; 23(10):1380-1392. PubMed ID: 34325056
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a gene expression tumour classifier for cancer of unknown primary.
Tothill RW; Shi F; Paiman L; Bedo J; Kowalczyk A; Mileshkin L; Buela E; Klupacs R; Bowtell D; Byron K
Pathology; 2015 Jan; 47(1):7-12. PubMed ID: 25485653
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary.
Laprovitera N; Riefolo M; Porcellini E; Durante G; Garajova I; Vasuri F; Aigelsreiter A; Dandachi N; Benvenuto G; Agostinis F; Sabbioni S; Berindan Neagoe I; Romualdi C; Ardizzoni A; Trerè D; Pichler M; D'Errico A; Ferracin M
Mol Oncol; 2021 Oct; 15(10):2732-2751. PubMed ID: 34075699
[TBL] [Abstract][Full Text] [Related]
16. A second-generation microRNA-based assay for diagnosing tumor tissue origin.
Meiri E; Mueller WC; Rosenwald S; Zepeniuk M; Klinke E; Edmonston TB; Werner M; Lass U; Barshack I; Feinmesser M; Huszar M; Fogt F; Ashkenazi K; Sanden M; Goren E; Dromi N; Zion O; Burnstein I; Chajut A; Spector Y; Aharonov R
Oncologist; 2012; 17(6):801-12. PubMed ID: 22618571
[TBL] [Abstract][Full Text] [Related]
17. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.
Schipper LJ; Samsom KG; Snaebjornsson P; Battaglia T; Bosch LJW; Lalezari F; Priestley P; Shale C; van den Broek AJ; Jacobs N; Roepman P; van der Hoeven JJM; Steeghs N; Vollebergh MA; Marchetti S; Cuppen E; Meijer GA; Voest EE; Monkhorst K
ESMO Open; 2022 Dec; 7(6):100611. PubMed ID: 36463731
[TBL] [Abstract][Full Text] [Related]
18. A molecular approach integrating genomic and DNA methylation profiling for tissue of origin identification in lung-specific cancer of unknown primary.
Chen K; Zhang F; Yu X; Huang Z; Gong L; Xu Y; Li H; Yu S; Fan Y
J Transl Med; 2022 Apr; 20(1):158. PubMed ID: 35382836
[TBL] [Abstract][Full Text] [Related]
19. Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
Leibowitz BD; Dougherty BV; Bell JSK; Kapilivsky J; Michuda J; Sedgewick AJ; Munson WA; Chandra TA; Dry JR; Beaubier N; Igartua C; Taxter T
BMC Cancer; 2022 May; 22(1):587. PubMed ID: 35643464
[TBL] [Abstract][Full Text] [Related]
20. Application of a Neural Network Whole Transcriptome-Based Pan-Cancer Method for Diagnosis of Primary and Metastatic Cancers.
Grewal JK; Tessier-Cloutier B; Jones M; Gakkhar S; Ma Y; Moore R; Mungall AJ; Zhao Y; Taylor MD; Gelmon K; Lim H; Renouf D; Laskin J; Marra M; Yip S; Jones SJM
JAMA Netw Open; 2019 Apr; 2(4):e192597. PubMed ID: 31026023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
